Clinicians should avoid using the imaging agents regadenoson (Lexiscan, Astellas Pharma US) and adenosine (Adenoscan, Astellas Pharma US) for cardiac nuclear stress tests of patients with signs or ...
Lexiscan is the first A2A adenosine receptor agonist shown to be safe and effective as a pharmacologic stress agent in MPI studies. Lexiscan is delivered as a rapid bolus (approximately 10 seconds) ...
San Francisco, CA—Regadenoson yielded similar Fractional Flow Reserve (FFR) measurements as adenosine in a cohort of patients with angiographic CAD. Lokien van Nunen MD, of Catharina Hospital ...
Point LomaPoint Loma — A new approach to reducing sickle cell anemia’s painful attacks has entered Phase II clinical trials. The drug, Lexiscan, is already approved for diagnosing heart disease.
Fourteen years after it launched Lexiscan in the U.S., Astellas is trying to wring the last bit of market exclusivity it can get out of the scanning agent. In federal court last week in Delaware, ...
The drug regadenoson is safe and poses fewer side effects than the conventional medication used during a cardiac nuclear stress test of heart transplant patients, according to a Henry Ford Hospital ...
Lexiscan approved for MPI testing Lexiscan (regadenoson injection, from Astellas), a pharmacologic stress agent, is now available for use in radionuclide myocardial perfusion imaging (MPI) for ...
Lexiscan is the first A2A adenosine receptor agonist shown to be safe and effective as a pharmacologic stress agent in MPI studies. Lexiscan is delivered as a rapid bolus (approximately 10 seconds) ...
PALO ALTO, Calif. and DEERFIELD, Ill., April 10 -- CV Therapeutics and Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lexiscan(TM) (regadenoson) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results